The Sunnyvale, California based Arrayit Corporation has quickly evolved into a leader in the genetic, research, and diagnostic communities through the development and manufacture of state-of-the-art life science technologies which combat diseases. Today, the young corporation made national news with the announcement that the prestigious Johns Hopkins University School of Medicine in Baltimore, Maryland purchased their technology to study rheumatoid arthritis.

Johns Hopkins strongly endorsed the Arrayit Platform and the NanoPrint robot for their evolutionary technical capabilities. The historic University is also considering Arrayit’s consumable stream of substrates and reagents.

Arrayit’s NanoPrint platforms have been installed at other major research and diagnostic centers across the United States and are becoming the benchmark in their field.

When asked about the impact of the NanoPrint, Dr. Heng Zhu who is an Assistant Professor at Johns Hopkins, was quoted as saying, “Because of the high capacity of the NanoPrint, we use it to print 17,000 human proteins on a single glass slide. You can see all 17,000 proteins for their auto-immunity, covering 80% of the human proteome. We call that The Human Proteome Chip.”

There seems to be a consensus in the medical community that Arrayit Technology is becoming a leader of technology. Currently, Arrayit is trading in the $1.00 range and well off of its 52 week low of $0.05. Investors should examine what Arrayit has to offer because it may only be a matter of time before the California Corporation turns from a hidden over-the-counter gem into a widely known stock amongst the investment community.

Let’s hear your thoughts below: